Literature DB >> 9021941

Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis.

A J Czaja1, M D Strettell, L J Thomson, P J Santrach, S B Moore, P T Donaldson, R Williams.   

Abstract

Susceptibility for type 1 autoimmune hepatitis has been associated with the major histocompatibility alleles DRB1*0301, DRB3*0101, DRB1*0401, and DRB4*0103, whereas the DRB1*1501 allele may protect from the disease. Our aim was to determine if these alleles or others influence clinical manifestations and prognosis. Eighty-six white patients were evaluated prospectively for immune features and outcomes. Class I alleles were determined by microlymphocytotoxicity, and class II alleles were assessed by polymerase chain reaction with sequence-specific oligonucleotide probes or sequence-specific primers. One hundred two white, normal subjects were typed in the same fashion. Patients with concurrent immunologic diseases were more commonly positive for DRB4*0103 than patients without these features (68% vs. 38%, P = .01). DRB1*0301 (86% vs. 45%, P = .008) and the DRB1*0301-DRB3*0101 haplotype (79% vs. 42%, P = .02) occurred more commonly in patients who deteriorated during corticosteroid therapy. In contrast, DRB1*0401 and the DRB1*0401-DRB4*0103 haplotype were associated with a lower frequency of death from liver failure or the need for transplantation than patients with other alleles (0% vs. 37%, P = .03). Patients with DRB1*0301 differed from those with DRB1*0401 in that they were younger and failed treatment more commonly (27% vs. 5%, P = .04). We conclude that alleles associated with susceptibility to type 1 autoimmune hepatitis also influence its clinical features and prognosis. DRB4*0103 is associated with concurrent immune diseases, DRB1*0301 with a poor treatment response, and DRB1*0401 with a lower frequency of hepatic death or transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021941     DOI: 10.1002/hep.510250211

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  52 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 2.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

Review 3.  Advances in the current treatment of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

Review 4.  Autoantibodies as prognostic markers in autoimmune liver disease.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

5.  Relationship between autoimmune hepatitis and HLA-DR4 and DRbeta allelic sequences in the third hypervariable region in Chinese.

Authors:  X Ma; D K Qiu
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

6.  The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis.

Authors:  I G McFarlane
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

Review 7.  Pathogens and autoimmune hepatitis.

Authors:  U Christen; E Hintermann
Journal:  Clin Exp Immunol       Date:  2018-10-07       Impact factor: 4.330

8.  Autoimmune hepatitis in a genetically susceptible patient: is it triggered by acute viral hepatitis A?

Authors:  N Hilzenrat; D Zilberman; T Klein; B Zur; E Sikuler
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

Review 9.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

Review 10.  Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma.

Authors:  Lydia Giannitrapani; Maurizio Soresi; Daniele Balasus; Anna Licata; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.